You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Harvard Business School
McKinsey
Boehringer Ingelheim
Dow

Last Updated: February 24, 2020

DrugPatentWatch Database Preview

Litigation Details for Shire Development LLC v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Shire Development LLC v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)

Docket   Start Trial Date Filed 2017-11-22
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To Richard Gibson Andrews
Jury Demand None Referred To
Parties ACTAVIS LABORATORIES FL, INC.; IMPAX LABORATORIES LLC; SHIRE DEVELOPMENT LLC; SHIRE LLC; SHIRE US INC.; SPECGX LLC; TEVA PHARMACEUTICALS INDUSTRIES LIMITED; TEVA PHARMACEUTICALS USA INC.
Patents 6,913,768; 8,846,100; 9,173,857
Attorneys Andrew S. Roper; Brian T. Drummond; C. Kyle Musgrove; Daryl L. Wiesen; David A. Bilson; Derek James Fahnestock; Dominick T. Gattuso; Edgar H. Haug; Elizabeth M. Crompton; Emily L. Rapalino; Enes Ovcina; Jack B. Blumenfeld; John C. Phillips , Jr.; John P. Snow; Karen Elizabeth Keller; Karen Jacobs; Kevin J. Georgek; Laura A. Chubb; Mark T. Deming; Nathan Roger Hoeschen; Nicholas F. Giove; Randal S. Alexander; Sandra Kuzmich; Sarah J Fischer
Firms Heyman Enerio Gattuso & Hirzel LLP; Morris, Nichols, Arsht & Tunnell; Phillips, Goldman, McLaughlin & Hall, P.A.; Shaw Keller LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Shire Development LLC v. Teva Pharmaceuticals USA, Inc.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Shire Development LLC v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)

Date Filed Document No. Description Snippet Link To Document
2019-02-28 109 in U.S. Patent Nos. 6,913,768 ('"768 Patent"), 8,846,100 ("'100 Patent"),…construction for multiple terms in U.S. Patent Nos. 6,913,768, 8,846,100, and 9,173,857. Within five …claim 1 of the ' 100 Patent and claim 1 of the ' 857 Patent. The Patents relate to "a long-acting…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which …construing patent claims, a court considers the literal language of the claim, the patent specification External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Dow
Baxter
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.